Financial Ratios Cizzle Biotechnology Holdings Plc
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.450 GBX | 0.00% |
|
-6.45% | -6.45% |
| 05/11 | Cizzle Biotechnology Raises Funds via Convertible Loan Note Issue | MT |
| 05/11 | Cizzle Biotechnology announces LOI with leading UK clinical diagnostic group | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -66.1 | -85.62 | -30.55 | -27.24 | -50.11 | |||||
Return on Total Capital | -202.78 | -106.23 | -33.65 | -29.42 | -68.91 | |||||
Return On Equity % | 2.05T | -844.13 | -50.99 | -82.81 | -272.62 | |||||
Return on Common Equity | 2.05T | -844.13 | -50.99 | -82.81 | -272.62 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | - | - | - | - | - | |||||
SG&A Margin | - | - | - | - | - | |||||
EBITDA Margin % | - | - | - | - | - | |||||
EBITA Margin % | - | - | - | - | - | |||||
EBIT Margin % | - | - | - | - | - | |||||
Income From Continuing Operations Margin % | - | - | - | - | - | |||||
Net Income Margin % | - | - | - | - | - | |||||
Net Avail. For Common Margin % | - | - | - | - | - | |||||
Normalized Net Income Margin | - | - | - | - | - | |||||
Asset Turnover | ||||||||||
Asset Turnover | - | - | - | - | - | |||||
Fixed Assets Turnover | - | - | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.56 | 4.38 | 4.86 | 9.1 | 1.2 | |||||
Quick Ratio | 0.39 | 4.25 | 3.95 | 8.96 | 1.13 | |||||
Operating Cash Flow to Current Liabilities | -0.89 | -4.63 | -6.01 | -3.44 | -0.87 | |||||
Average Days Payable Outstanding | - | - | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -125 | - | - | - | - | |||||
Total Debt / Total Capital | 500 | - | - | - | - | |||||
Total Liabilities / Total Assets | 180 | 18.87 | 5.21 | 10.99 | 83.33 | |||||
Net Debt / EBITDA | - | - | - | - | - | |||||
Net Debt / (EBITDA - Capex) | - | - | - | - | - | |||||
Growth Over Prior Year | ||||||||||
Gross Profit, 1 Yr. Growth % | - | - | - | - | - | |||||
EBITDA, 1 Yr. Growth % | - | - | - | - | - | |||||
EBITA, 1 Yr. Growth % | -35.51 | 5.6T | 13.16 | 1.35 | -10.25 | |||||
EBIT, 1 Yr. Growth % | -35.51 | 5.6T | 13.16 | 1.35 | -10.25 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -35.51 | 27.91T | -76.74 | 88.27 | 26.15 | |||||
Net Income, 1 Yr. Growth % | -35.51 | 27.91T | -76.74 | 88.27 | 26.15 | |||||
Normalized Net Income, 1 Yr. Growth % | -35.51 | 5.98T | 13.16 | 1.35 | -18.44 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -59 | -13.83 | -87.19 | 54.12 | 15.88 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | - | - | - | |||||
Total Assets, 1 Yr. Growth % | -39.31 | 11.45T | 141.13 | -39.21 | -70.94 | |||||
Tangible Book Value, 1 Yr. Growth % | -220.65 | -9.31T | -24.02 | 169.11 | -94.56 | |||||
Common Equity, 1 Yr. Growth % | -220.65 | -11.81T | 181.75 | -42.92 | -94.56 | |||||
Cash From Operations, 1 Yr. Growth % | 126.24 | 6.21T | -13.58 | -26.72 | -43.98 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -1.03T | -26.33T | -126.19 | -74.62 | -39.47 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -1.03T | -26.33T | -126.19 | -74.62 | -39.47 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Gross Profit, 2 Yr. CAGR % | - | - | - | - | - | |||||
EBITDA, 2 Yr. CAGR % | - | - | - | - | - | |||||
EBITA, 2 Yr. CAGR % | 120.02 | 506.28 | 729.37 | 7.09 | -4.62 | |||||
EBIT, 2 Yr. CAGR % | 120.02 | 506.28 | 729.37 | 7.09 | -4.62 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 120.25 | 1.24T | 707.11 | -33.83 | 54.11 | |||||
Net Income, 2 Yr. CAGR % | 120.25 | 1.24T | 707.11 | -33.83 | 54.11 | |||||
Normalized Net Income, 2 Yr. CAGR % | 120.3 | 526.1 | 729.37 | 7.09 | -9.08 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 75.61 | -40.56 | -66.77 | -55.56 | 33.64 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | - | - | - | |||||
Total Assets, 2 Yr. CAGR % | -54.85 | 737.24 | 1.57T | 21.07 | -57.97 | |||||
Tangible Book Value, 2 Yr. CAGR % | -46.87 | 954.25 | 736.66 | 43 | -61.73 | |||||
Common Equity, 2 Yr. CAGR % | -46.87 | 1.09T | 1.72T | 26.82 | -82.38 | |||||
Cash From Operations, 2 Yr. CAGR % | 56.1 | 1.09T | 638.24 | -20.42 | -35.93 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 14.01 | 4.84T | 723.54 | -74.22 | -60.81 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 14.01 | 4.84T | 723.54 | -74.22 | -60.81 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | - | - | - | - | - | |||||
Gross Profit, 3 Yr. CAGR % | - | - | - | - | - | |||||
EBITDA, 3 Yr. CAGR % | - | - | - | - | - | |||||
EBITA, 3 Yr. CAGR % | -53.57 | 551.03 | 253.99 | 311.57 | 0.97 | |||||
EBIT, 3 Yr. CAGR % | -53.57 | 551.03 | 253.99 | 311.57 | 0.97 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -50.89 | 1.01T | 247.64 | 396.84 | -17.95 | |||||
Net Income, 3 Yr. CAGR % | -50.89 | 1.01T | 247.64 | 396.84 | -17.95 | |||||
Normalized Net Income, 3 Yr. CAGR % | -53.57 | 565.69 | 253.99 | 311.57 | -2.2 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -57.77 | 38.51 | -64.36 | -44.59 | -38.83 | |||||
Total Assets, 3 Yr. CAGR % | -38.56 | 186.62 | 452.9 | 453.2 | -24.76 | |||||
Tangible Book Value, 3 Yr. CAGR % | -36.49 | 196.27 | 338.74 | 473.25 | -51.9 | |||||
Common Equity, 3 Yr. CAGR % | -36.49 | 220.96 | 635.66 | 473.25 | -55.6 | |||||
Cash From Operations, 3 Yr. CAGR % | -53.41 | 435.63 | 397.73 | 241.82 | -29.21 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -56.23 | 598.61 | 757.97 | 158.18 | -65.74 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -56.23 | 598.61 | 757.97 | 158.18 | -65.74 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
EBITA, 5 Yr. CAGR % | -41.18 | 32.68 | 47.09 | 220.37 | 109.49 | |||||
EBIT, 5 Yr. CAGR % | -41.18 | 32.68 | 47.09 | 220.37 | 109.49 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -38.98 | 89.76 | 50.48 | 258.84 | 151.08 | |||||
Net Income, 5 Yr. CAGR % | -38.98 | 89.76 | 50.48 | 258.84 | 151.08 | |||||
Normalized Net Income, 5 Yr. CAGR % | -41.14 | 34.42 | 47.09 | 220.53 | 105.52 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | -45.49 | -61.63 | -12.1 | -39.53 | |||||
Total Assets, 5 Yr. CAGR % | -52.02 | 38.77 | 130.17 | 103.05 | 97.25 | |||||
Tangible Book Value, 5 Yr. CAGR % | -52.09 | 36.14 | 78.13 | 121.38 | 65.37 | |||||
Common Equity, 5 Yr. CAGR % | -52.09 | 42.84 | 142.9 | 121.38 | 65.37 | |||||
Cash From Operations, 5 Yr. CAGR % | - | - | 40.69 | 149.83 | 119.21 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 41.58 | 86.18 | 149.66 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 41.58 | 86.18 | 149.66 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















